TY - JOUR
T1 - Adenosine deaminase activity in peripheral lymphocytes of patients with gynaecologic malignancies.
AU - Specchia, G.
AU - Pavone, V.
AU - Maggio, F.
AU - Lojudice, L.
AU - Iacobazzi, A.
AU - De Tullio, L.
AU - Cagnazzo, G.
AU - Liso, V.
PY - 1985
Y1 - 1985
N2 - Peripheral lymphocyte adenosine deaminase (ADA) activity was assessed in a group of 31 patients with gynaecologic malignancies (19 with carcinoma of the portio, 7 with endometrial adenocarcinoma, 3 with ovarian cancer, 1 with adenocarcinoma of the cervix, 1 with liposarcoma myxoide). 30 female subjects, aged 30 to 70 years, were studied as the control group. Lymphocyte ADA activity in the 31 patients ranged from 0 to 7 U/10(7) cells with a mean of 2.3 U/10(7) cells (normal values: range 2-5 U/10(7) cells; mean 2.8 U/10(7) cells). In cases where the enzyme was absent or far below the controls, a faster evolution of the disease was observed. We would point out that lymphocyte ADA activity in the patients under investigations shows a broad range of variability. Our preliminary observations would suggest that lymphocyte ADA assessment in a larger series of cancer patients may add further prognostic informations.
AB - Peripheral lymphocyte adenosine deaminase (ADA) activity was assessed in a group of 31 patients with gynaecologic malignancies (19 with carcinoma of the portio, 7 with endometrial adenocarcinoma, 3 with ovarian cancer, 1 with adenocarcinoma of the cervix, 1 with liposarcoma myxoide). 30 female subjects, aged 30 to 70 years, were studied as the control group. Lymphocyte ADA activity in the 31 patients ranged from 0 to 7 U/10(7) cells with a mean of 2.3 U/10(7) cells (normal values: range 2-5 U/10(7) cells; mean 2.8 U/10(7) cells). In cases where the enzyme was absent or far below the controls, a faster evolution of the disease was observed. We would point out that lymphocyte ADA activity in the patients under investigations shows a broad range of variability. Our preliminary observations would suggest that lymphocyte ADA assessment in a larger series of cancer patients may add further prognostic informations.
UR - http://www.scopus.com/inward/record.url?scp=0022296312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022296312&partnerID=8YFLogxK
M3 - Article
C2 - 4091978
AN - SCOPUS:0022296312
VL - 64
SP - 404
EP - 407
JO - Bollettino dell'Istituto Sieroterapico Milanese
JF - Bollettino dell'Istituto Sieroterapico Milanese
SN - 0021-2547
IS - 5
ER -